INOVIO Reports 100% Antibody Efficacy in COVID-19 Trial

INOVIO has reported promising interim results from a Phase 1 proof-of-concept trial of DNA-encoded monoclonal antibodies (dMAbs) for COVID-19, with all 24 participants maintaining biologically relevant antibody levels after 72 weeks. The study, conducted in collaboration with AstraZeneca and the Perelman School of Medicine, found no cases of anti-drug antibodies, which are often problematic in gene-based therapies. The dMAbs were well tolerated, with mild injection site reactions being the most common side effects. This trial represents a significant step in demonstrating the potential of dMAb technology to provide durable and effective treatments for infectious diseases. Researchers highlight that this approach could transform therapies for a range of conditions, including cancer and metabolic disorders. The findings are expected to be presented at scientific conferences in 2025.